4-(4-propan-2-ylpiperazin-1-yl)phenol

We are 4-(4-propan-2-ylpiperazin-1-yl)phenol CAS:67914-97-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 4-(4-propan-2-ylpiperazin-1-yl)phenol
CAS.NO:  67914-97-0    
Synonyms:
4-(4-Isopropyl-piperazin-1-yl)-phenol
4-(4-isopropyl-1-piperazinyl)phenol
p-(4-isopropyl-1-piperazinyl)phenol
1-ISOPROPYL-4-(4-HYDROXYPHENYL)PIPERAZINE
1-(4-hydroxyphenyl)-4-(1-methylethyl)piperazine
4-(4-hydroxyphenyl)-1-(1-methylethyl)piperazine

Molecular Formula: C13H20N2O
Molecular Weight:  220.31100

Physical and Chemical Properties:
Density:1.083±0.06 g/cm3
Boiling point: 364.8±37.0 °C
Melting point: 274.4 °C
Flash point:/
Refractive index: /

Specification:
Appearance: crystallization
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Refrigerator.Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Sibutramine Hydrochloride CAS:84485-00-7

Related News: The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.N- (2-cloropirimidin-4-il) -2,3-dimetilindazol-6-amina CAS:444731-74-2 The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.4-hidroxibenzotioamida CAS:25984-63-8 Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.4-Methyl-3-(trifluoromethyl)benzoic acid The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform.